Lumos Diagnostics Holdings Limited
Australian Securities ExchangeRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Lumos Diagnostics Holdings Limited is a leader in developing and marketing swift, point-of-care diagnostic tests, primarily focusing on managing and identifying infectious diseases for healthcare systems in North America and Europe. The company delivers innovative solutions such as FebriDx, a diagnostic test designed to distinguish between bacterial and viral respiratory illnesses to support targeted treatment decisions, and ViraDx, a comprehensive three-in-one test for influenza A, influenza B, and COVID-19. Lumos also provides contract development and manufacturing services for customized diagnostic assays and offers its proprietary digital reader platforms. Established in 2004, the company maintains a presence in Melbourne, Australia, and Carlsbad, California. Notably, Lumos recently secured full U.S. Medicare reimbursement for its FebriDx test, enhancing its market penetration.
Dow Jones closes above 52,000 for the first time as US-Iran truce holds
Lumos Diagnostics receives A$710,000 R&D tax rebate to support point-of-care technology development
US commercialisation of FebriDx® to be discussed at Lumos Webinar: Thursday, June 11, at 10:30am AEST
Five Below shares fall as tariff assumptions draw focus from earnings beat
FTSE 100 Live: Stocks vacillating, CMC surges, SpaceX to IPO next week
Lumos sees strong early reimbursement signals as FebriDx® rollout gains traction in US urgent care market
Small Cap Watch: Small Caps mixed as Elixir, Ora Banda, Lumos and Scorpion deliver key updates
Lumos hits major US regulatory milestone with FebriDx study support
Nasdaq set to lead the charge higher as Wall Street looks to jobs report
AppLovin tops Q1 earnings expectations on AI-driven ad growth
Boeing continues to show turnaround progress, keeping Banking of America bullish
Lumos Diagnostics raises $265,000 through share purchase plan as FebriDx rollout gathers pace
Agnico Eagle to buy Rupert, Aurion in $3B Finland consolidation drive
Lumos pivots to commercial growth phase following FebriDx breakthrough
Cleveland Cliffs shares fall as higher costs overshadow Q1 earnings beat
FTSE 100 Live: Shares mixed as Iran talks awaited, Ceres and Rank jump
Nasdaq and Dow Jones set for flat start as Trump hails 'amazing' Iran talks in two days
Lumos Diagnostics expands WellStreet rollout to 43 sites as FebriDx gains US traction
OpenAI acquires personal finance startup Hiro Finance, service to wind down in April
Lumos secures US$5m FebriDx milestone payment as US rollout gains traction